Gilead Becomes Third To Market In Second-Line PBC, With Label Advantages

Gilead will make the case that Livdelzi is a better treatment option than Ocaliva or recently approved Iqirvo due to its ability to alleviate pruritus and reduce ALP levels.

FDA approved
Gilead is third to market in second-line PBC therapy with Livdelzi

Gilead Sciences, Inc. made a substantial bet on moving into a different kind of liver disease with its $4.3bn takeout in February of CymaBay Therapeutics, Inc., and that transaction is beginning to bear fruit with the US Food and Drug Administration approval on 14 August of Livdelzi (seladelpar) for second-line treatment of primary biliary cholangitis (PBC). In that setting, Livdelzi will compete against two second-line agents, Alfasigma S.p.A.’s Ocaliva (obeticholic acid), approved in 2016, and Ipsen SA/Genfit SA’s Iqirvo (elafibranor), which obtained FDA approval in June.

In an interview with Scrip, Gilead executive director of global medical affairs for liver diseases Carrie Frenette declined to offer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.

Pipeline Watch: Twelve Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

 

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

More from Scrip

EU 15% Tariff Deal Still Leaves Questions For Pharma

 

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.